SCHEMBL19989468

SCHEMBL19989468

CC1(C)OB(c2ccc3[nH]nc(N)c3c2F)OC1(C)C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 6/20 0.37
LCK P06239 4/20 0.37
CSF1R P07333 4/20 0.37
FLT1 P17948 3/20 0.37
MAP2K1 Q02750 2/20 0.37
FGFR1 P11362 2/20 0.37
PRKACA P17612 2/20 0.37
ROCK1 Q13464 2/20 0.37
ABL1 P00519 2/20 0.37
DAPK3 O43293 1/20 0.37
PRKD3 O94806 1/20 0.37
MAP4K4 O95819 1/20 0.37
PAK4 O96013 1/20 0.37
NTRK1 P04629 1/20 0.37
RET P07949 1/20 0.37
IGF1R P08069 1/20 0.37
MET P08581 1/20 0.37
PDGFRB P09619 1/20 0.37
LTK P29376 1/20 0.37
GRK5 P34947 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29859747 1.00 KDR (0.37) KDRLCKCSF1RFLT1MAP2K1
SCHEMBL19989510 0.84 PDPK1 (0.36) KDRLCKCSF1RFLT1MAP2K1
SCHEMBL29859216 0.84 GAA (0.43) KDRLCKCSF1RFLT1MAP2K1
SCHEMBL19989547 0.84 GAA (0.43) KDRLCKCSF1RFLT1MAP2K1
SCHEMBL29859433 0.84 PDPK1 (0.36) KDRLCKCSF1RFLT1MAP2K1
SCHEMBL29859572 0.81 PDPK1 (0.34) KDRLCKCSF1RFLT1MAP2K1
SCHEMBL19989450 0.81 PDPK1 (0.34) KDRLCKCSF1RFLT1MAP2K1
SCHEMBL22531558 0.79 CHEK1 (0.34) KDRCSF1RFGFR1MAP4K4LTK
SCHEMBL29859278 0.78 LPL (0.33) KDRGAAKITFLT3LPL
SCHEMBL19989538 0.78 LPL (0.33) KDRGAAKITFLT3LPL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109715608-B Indazole compounds for use in tendon and/or ligament injuries 诺华股份有限公司 2022-08-05 CN disclosed
EP-3515894-B1 INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES NOVARTIS AG (CH) 2021-04-07 EP disclosed
EP-3515894-A1 INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES Novartis AG (CH) 2019-07-31 EP disclosed
US-10112907-B2 Substituted indazoles for treating tendon and/or ligament injuries NOVARTIS AG (CH) 2018-10-30 US disclosed
US-20180086716-A1 Indazole Compounds for Use in Tendon and/or Ligament Injuries NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA THE GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION 2018-03-29 US disclosed
WO-2018055550-A1 INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES NOVARTIS AG (CH) 2018-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10112907-B2 Substituted indazoles for treating tendon and/or ligament injuries SLC10A2, MMP1, TNNI3 KDR 4765/4885LCK 2700/4885CSF1R 2496/4885
US-20180086716-A1 Indazole Compounds for Use in Tendon and/or Ligament Injuries MMP1, SLC10A2, TNNI3 KDR 4836/4885LCK 3108/4885CSF1R 3237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.